Fund Evaluator:
Renaissance IPO ETF (IPO)Equity
Global Asset Class
U.S. Equity
Fund Group
Mid-Cap Growth
Category
$28.564
NAV (as of Oct 07)
$0.00
Minimum Initial
0.60% C
Expense Ratio
$148 Mil
Assets
Open
Status
na
12b-1 Fee
0.46%
TTM Yield
0.00%
Max Load
93%
Portfolio Turnover
Best Performing in Mid-Cap Growth Over the Last Year
| 44.9% | PRIMECAP Odyssey Aggressive Growth (POAGX) |
| 27.1% | Eventide Gilead N (ETGLX) |
| 23.3% | Sit Small Cap Growth (SSMGX) |
| 19.8% | Goldman Sachs Small/Mid Cap Growth Inv (GTMTX) |
| 19.2% | ProFunds Mid Cap Growth Inv (MGPIX) |
Data as of 7/31/2026
-14.2% F
1-Mo Return
5.4% A
3-Mo Return
12.1% B
YTD Return
11.5% C
1-Yr Return
12.1% D
3-Yr Return
-3.8% F
5-Yr Return
1.34 F
Category Risk Index
2.31
Total Risk Index
Fund Details
Fund Family
Renaissance Capital
Inception Date
10/16/2013
Share Class Type
Equity Investment Style
Mid-Cap
Growth
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
Yes
Benchmark Index
S&P 500 (TR) (1970): 100%
Additional Fund Details
Renaissance IPO ETF Overview
IPO Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| IPO Return (NAV) | -14.2% | 5.4% | 11.5% | 12.1% | -3.8% | 10.0% |
| IPO Grade | F | A | C | D | F | D |
| +/- Category | -8.6% | 3.3% | 6.0% | 1.6% | -6.3% | -0.9% |
| Mid-Cap Growth Avg | -5.5% | 2.1% | 5.5% | 10.5% | 2.5% | 10.9% |
| IPO Tax Cost Ratio | na | na | 0.2% | 0.1% | 0.1% | 0.1% |
IPO Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| IPO Return (NAV) | 12.1% | 5.4% | 15.8% | 52.4% | -57.2% | -10.2% | 107.3% | 34.3% | -17.1% | 36.7% | -0.2% |
| IPO Grade | B | D | D | A | F | F | A | B | F | A | F |
| +/- Category | 6.4% | -0.7% | -1.5% | 31.6% | -29.2% | -22.5% | 66.9% | 0.4% | -12.5% | 11.4% | -5.5% |
| Mid-Cap Growth Avg | 5.7% | 6.1% | 17.3% | 20.8% | -28.1% | 12.3% | 40.4% | 33.9% | -4.6% | 25.3% | 5.3% |
| Risk Measures | |
| Standard Deviation: | 28.3% |
| Total Risk Index: | 2.31 - High |
| Category Risk Index: | 1.34 - High |
| Category Risk Grade: | F (89% Rank) |
| Beta: | 1.66 |
| R-Squared: | 59% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Mid-Cap Growth |
| Bond Investment Style: | na |
| Yield: | 0.5% |
| Dividend Distribution: | Quarterly |
| Cap Gains Distribution: | |
| Total Assets: | $148 Mil |
| Fund Total Assets: | $ 148 Mil |
| Share Class Type: | |
| Portfolio Turnover: | 93% |
Management Team
| Number of Managers: 1 | |||
| Longest Tenure: 5.5 years | |||
| Average Tenure: 5.5 years | |||
| Managers (Year): Ng Tiffany (2021) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 53 |
| % in Top 10 Holdings: | 56.5% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 5.8% |
Portfolio Allocation |
|
| Domestic Stock: | 94.1% |
| Foreign Stock: | 5.8% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.2% |
Purchase Information
| Fund Family: | Renaissance Capital |
| Phone Number: | 866-486-6645 |
| Website: | www.renaissancecapital.com |
| Status: | Open |
| Inception Date: | October 16, 2013 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | na |
Expenses and Fees | |
| Expense Ratio (%): | 0.60% ( Rating : Above Avg ) |
| Category Average Expense Ratio (%): | 1.09% |
| Share Class: | Renaissance IPO ETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.